SJX-653 / Lundbeck, Sojournix - LARVOL DELTA

Phase 2 Study of SJX-653 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms (clinicaltrials.gov) - P2; N=13; Terminated; Sponsor: Sojournix, Inc.; N=66 ➔ 13; Trial completion date: Sep 2021 ➔ Mar 2021; Recruiting ➔ Terminated; Trial primary completion date: Sep 2021 ➔ Mar 2021; Decision to terminate the study as anticipated target profile (confirmation of the selected dose of SJX-653 as safe and efficacious for further development for the treatment of moderate to severe vasomotor symptoms in postmenopausal women) not met

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination

Phase 2 Study of SJX-653 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms (clinicaltrials.gov) - P2; N=66; Recruiting; Sponsor: Sojournix, Inc.; Suspended ➔ Recruiting; N=130 ➔ 66; Initiation date: Aug 2020 ➔ Nov 2020

Clinical • Enrollment change • Enrollment open • Trial initiation date

Commentary on "Pharmacodynamic activity of the novel neurokinin-3 receptor antagonist SJX-653 in healthy men". (PubMed, J Clin Endocrinol Metab) - No abstract available

Clinical • Journal • PK/PD data

Pharmacodynamic activity of the novel neurokinin-3 receptor antagonist SJX-653 in healthy men. (PubMed, J Clin Endocrinol Metab) - "These data demonstrate clinical proof-of-mechanism for SJX-653 as a potent centrally-acting NK3R antagonist."

Clinical • Journal • PK/PD data

Phase 2 Study of SJX-653 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms (clinicaltrials.gov) - P2; N=130; Suspended; Sponsor: Sojournix, Inc.; Trial completion date: Feb 2021 ➔ Aug 2021; Initiation date: Feb 2020 ➔ Aug 2020; Recruiting ➔ Suspended; Trial primary completion date: Feb 2021 ➔ Aug 2021

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Trial suspension